Prescient Therapeutics Ltd has received Fast Track Designation from the United States Food and Drug Administration (FDA) for its lead candidate PTX-100, putting the company closer to potential Accelerated Approval – a central component of its commercialisation strategy.
The designation, which applies to the treatment of adults with relapsed or refractory (r/r) mycosis fungoides – the most common subtype of Cutaneous T Cell Lymphoma (CTCL) – offers Prescient several regulatory advantages. These include increased access to the FDA and the ability to submit New Drug Applications (NDAs) on a rolling basis, expediting the review process for PTX-100.
This development marks a key milestone for the clinical-stage oncology company as it progresses PTX-100 as a potential treatment for a serious condition with high unmet medical need.
The FDA’s decision signals that existing trial data demonstrates encouraging therapeutic potential for patients who have limited options, even where alternative treatments exist in the US.
“Getting Fast-Track designation is a critical milestone towards our goal of advancing PTX-100 into a registration-enabling trial designed to support potential accelerated approval and, from there, commercialisation. As we progress our Phase 2 trials, we will be engaging closely with the FDA to ensure alignment on endpoints and study scope,” Prescient Therapeutics CEO, James McDonnell said.
Giving patients early access
Fast Track Designation is part of a broader FDA initiative to accelerate the development and review of drugs for serious conditions, enabling earlier patient access to new therapies. Prescient continues to build momentum with PTX-100, reinforcing its strategic focus on personalised cancer treatment.
Investors can learn more about the company’s progress at an online briefing hosted by McDonnell on Thursday, April 17 at 12:00 pm AEST. Registration is available via the company’s investor portal: https://prescienttherapeutics.investorportal.com.au/investor-briefing/.
PTX-100 targets key cancer enzyme in world-first clinical development
PTX-100 is a first-in-class compound designed to inhibit geranylgeranyl transferase-1 (GGT-1), a critical enzyme involved in cancer cell growth. By blocking GGT-1, PTX-100 disrupts oncogenic Ras signalling pathways, specifically inhibiting the activation of Rho, Rac and Ral circuits within cancer cells. This disruption leads to apoptosis, or programmed cell death, in malignant cells.
PTX-100 is currently believed to be the only GGT-1 inhibitor in clinical development worldwide. The compound has demonstrated a favourable safety profile and early clinical activity in both a Phase 1 trial and a recent pharmacokinetics/pharmacodynamics (PK/PD) basket study across haematological and solid tumour indications.
More recently, PTX-100 completed a Phase 1b expansion cohort study in patients with T cell lymphomas, where it delivered promising safety and efficacy signals. In recognition of its potential, the United States Food and Drug Administration (FDA) has granted PTX-100 Orphan Drug Designation for all T cell lymphomas.
A Phase 2 clinical trial in cutaneous T cell lymphoma (CTCL) is now underway, with the first study site activated and patient enrolment expected to commence imminently.